Skip to main content
. Author manuscript; available in PMC: 2012 Mar 1.
Published in final edited form as: Clin Immunol. 2011 Jan 21;138(3):311–320. doi: 10.1016/j.clim.2010.12.016

Figure 5.

Figure 5

Anti-CD3 mAb treatment protects mice from secondary induction of uveitis. (A) EAU score: B10RIII mice were immunized with IRBP161–180 on day 0 and/or day 30 and treated with 50 μg of anti-CD3 mAb or control Ab on days 6–10, then were sacrificed on day 50. + and - indicate whether the group was immunized on the indicated day. The EAU score observed by fundoscopy is two combined experiments with four mice per group. Score for each mouse is an average of both eyes. The results shown are the mean ± SD for the 8 mice. (B) Representative pathological results for each group at day 50. (C) Spleen and LN (n=4) were collected on day 50 and a proliferation assay in response to the indicated concentration of IRBP peptide measured. Shown (mean±SD) is a representative experiment of two with similar results.